Juvmo (tavapadon): FDA approval, pivotal trial and safety
Approved
Type
New molecular entity · Oral
FDA-approved use
To treat Parkinson’s disease in adultsWording from FDA's list of novel approvals.
FDA review
Standard review
Company
AbbVie
Application
NDA 220415
Specialty
Neurology
At a glance
Juvmo (tavapadon) is a non-ergot dopamine agonist approved by the FDA on September 25, 2026 for Parkinson's disease in adults. In two placebo-controlled studies of patients not taking levodopa, it improved MDS-UPDRS Part II scores at Week 26 compared with placebo; the label excerpt provided does not give the effect size. The main safety points are hypotension, impulse control problems, hallucinations and dyskinesia, with no boxed warning.
What it is and how it works
Tavapadon is a selective partial agonist at the dopamine D1 and D5 receptor subtypes. Dopamine agonists now in use mainly act on D2-family and D3 receptors. Tavapadon acts on a different receptor group, and it is not an ergot derivative.
27-week randomized, multicenter, double-blind, placebo-controlled trial with fixed-dose arms. Patients could continue into an open-label extension.
Patients
529 adults with early Parkinson's disease (modified Hoehn and Yahr stage 1 to 2) not taking levodopa; a stable MAO-B inhibitor was allowed. Mean age 63.7 years, 65% male, mean disease duration 0.8 years, mean baseline MDS-UPDRS Part II score 7.4.
Compared with
Placebo; two Juvmo dose arms (177 each) vs placebo (175).
Primary endpoint
Change from baseline in MDS-UPDRS Part II score at Week 26.
Result
Both Juvmo doses showed a statistically significant improvement vs placebo. The effect size, CI and P value are not in the label text provided.
Other results
Not given in the label excerpt provided.
Safety in the trial
Study 1 and Study 2 combined: adverse reactions led to discontinuation in 20% of Juvmo-treated patients, mostly during titration or adjustment. Orthostatic hypotension occurred in 5% vs 1% on placebo.
How does Juvmo (tavapadon) compare with the alternatives (Levodopa/carbidopa, D2/D3 dopamine agonists (pramipexole, ropinirole, rotigotine), MAO-B inhibitors (rasagiline, selegiline, safinamide)) for Parkinson’s disease in adults? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.
Ask in EvidencePulseOpens in a new tab. Nothing is sent until you press Ask. Free to try, more with 2MM+.
27-week randomized, multicenter, double-blind, placebo-controlled trial with flexible dosing.
Patients
304 adults with early Parkinson's disease not taking levodopa (151 Juvmo, 153 placebo).
Compared with
Placebo
Primary endpoint
Change from baseline in MDS-UPDRS Part II score at Week 26.
Result
Results are not given in the label excerpt provided.
Other results
Not given in the label excerpt provided.
Safety in the trial
Reported with Study 1 in the combined analysis. Common reactions were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth and anxiety.
There is no boxed warning. Warnings cover hypotension and orthostatic hypotension, impulse control and compulsive behaviors, hallucinations and psychotic-like behavior, and dyskinesia or worsening of existing dyskinesia. Orthostatic hypotension was reported in 5% of treated patients vs 1% on placebo without levodopa, and in 8% vs 2% as add-on to levodopa. Impulse control disorders were reported in 1% vs none without levodopa. The risk of hallucinations may be higher with strong CYP3A inhibitors. Without levodopa, the most common adverse reactions were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth and anxiety, and 20% of treated patients stopped because of an adverse reaction, mostly during titration or adjustment.
What it competes with
Parkinson's disease is treated with symptomatic drugs that restore dopaminergic signaling. Levodopa is the mainstay, and other agents are used early in disease or added as motor complications emerge.
Levodopa/carbidopaThe most effective symptomatic therapy and the standard for most patients; long-term use is linked to motor fluctuations and dyskinesia.
D2/D3 dopamine agonists (pramipexole, ropinirole, rotigotine)Used as initial therapy or as add-on; associated with impulse control disorders, somnolence and hypotension.
MAO-B inhibitors (rasagiline, selegiline, safinamide)Provide modest symptomatic benefit alone in early disease or as add-on to reduce off time.
COMT inhibitors (entacapone, opicapone)Extend levodopa effect in patients with wearing-off.
AmantadineUsed for dyskinesia and sometimes for early symptoms.
Bottom line for clinicians
Juvmo is an option for adults with Parkinson's disease, including early disease without levodopa and as add-on to levodopa. Weigh the high rate of discontinuation from adverse reactions during titration against the improvement in daily function. Monitor for orthostatic hypotension, impulse control problems, hallucinations and dyskinesia.
Dosing, contraindications and full warnings are in the prescribing information.
New FDA approvals in your inbox
The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.
Your subscription opens securely in a new tab.
Last updated October 28, 2026 by 2 Minute Medicine.
For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.
Get the app